Lv2
170 积分 2024-03-05 加入
Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed?
1天前
待确认
Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed?
22天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
22天前
已完结
Transferrin receptor targeting chimeras for membrane protein degradation
1个月前
已完结
Comparative expression of trophoblast cell-surface antigen 2 (TROP2) in the different molecular subtypes of invasive breast carcinoma: An immunohistochemical study of 94 therapy-naive primary breast tumors
1个月前
已完结
Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer
1个月前
已完结
The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention
2个月前
已完结
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
2个月前
已完结
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)
3个月前
已完结
Datopotamab Deruxtecan: First Approval
3个月前
已完结
皖公网安备34019202002308
